Redeye retains its positive view following a Q1 report matching our expectations.
Redeye will likely keep its forecasts and Base Case largely unchanged following a stable Q1 report m...
Mangold is updating its view on JonDeTech Sensors (JonDeTech).
Suominen’s Q1 earnings gained y/y, however the improvement pace was slower than we estimated as EBIT...
Redeye comments on the outcome of Oncopeptide's rights issue.
Q1 EBITDA of 13.0m, below ABGSCe USD 15m on higher costs No changes to guidance - Strategic review s...
Travere reported strong sales quarter growth for FILSPARI, competing with Calliditas TARPEYO.
Redeye comments on GiG’s Q1-results which were softer than expected, owing to somewhat lower-than-ex...
Suominen’s result were down slightly from Q4 and fell short of Vara Research consensus expectations.
Redeye concludes that Railcare had a solid start to the year.
Redeye will likely decrease its Base Case and forecasts following a soft Q1, hurt by adverse weather...
Redeye provides its initial comments on the Q1 2024 report from Scandinavian Chemotech, which was br...
Redeye comments on Nepa’s Q1-results which saw weaker topline than expected.
Redeye notes that Q1 sales were slightly lower than our estimates; however, EBIT aligned with our fo...
Redeye comments on MGI’s Q1 2024 report, which was roughly in line with our expectations.
Redeye comments on I-Tech’s Q1 figures beating our expectations across the board.
Net sales SEK 214m, 4% vs ABGSCe, 7% vs Factset cons.
Sales +24% and EBIT +52% vs. consensus Strong quarter with record-high turnover and profit Outlook r...
Redeye states that the Q1 report from Truecaller was better than expected.
Net sales and clean EBIT were below market consensus (LSEG) in Q1.
